Ikena Oncology Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
IMA$3.81-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Collaboration revenue | $— | $5,313 |
| Operating expenses: | ||
| Research and development | 9,645 | 15,552 |
| General and administrative | 5,999 | 5,276 |
| Restructuring and other charges | 2,582 | — |
| Total operating expenses | 18,226 | 20,828 |
| Loss from operations | (18,226) | (15,515) |
| Other income (expense): | ||
| Investment income | 2,114 | 1,296 |
| Other income (expense) | (7) | — |
| Total other income, net | 2,107 | 1,296 |
| Loss before income taxes | (16,119) | (14,219) |
| Income tax expense | (27) | — |
| Net loss | $(16,146) | $(14,219) |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on marketable securities | (265) | 272 |
| Total comprehensive loss | $(16,411) | $(13,947) |
| Net loss per share: | ||
| Net loss per share, basic and diluted | $(0.33) | $(0.39) |
| Weighted-average common shares outstanding, basic and diluted | 48,258,111 | 36,257,493 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.